Knowledge Hub

H2 2016 Interferon Alpha (IFNA) - Pipeline Review that is driven by industry demands illuminated by new report

Press Release   •   Jan 23, 2017 05:13 EST

Global Markets Directs, Interferon Alpha (IFNA) - Pipeline Review, H2 2016, provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interferon Alpha (IFNA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interferon Alpha (IFNA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

View Report @ http://www.marketresearchreports.biz/analysis/928077

Scope

- The report provides a snapshot of the global therapeutic landscape for Interferon Alpha (IFNA)

- The report reviews Interferon Alpha (IFNA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Interferon Alpha (IFNA) targeted therapeutics and enlists all their major and minor projects

- The report assesses Interferon Alpha (IFNA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Interferon Alpha (IFNA) targeted therapeutics

Get Sample Copy Of This Report @ http://www.marketresearchreports.biz/sample/sample/928077

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interferon Alpha (IFNA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interferon Alpha (IFNA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interferon Alpha (IFNA) Overview 6

Therapeutics Development 7

Interferon Alpha (IFNA) - Products under Development by Stage of Development 7

Interferon Alpha (IFNA) - Products under Development by Therapy Area 8

Interferon Alpha (IFNA) - Products under Development by Indication 9

Interferon Alpha (IFNA) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interferon Alpha (IFNA) - Products under Development by Companies 12

Interferon Alpha (IFNA) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interferon Alpha (IFNA) - Companies Involved in Therapeutics Development 21

Argos Therapeutics Inc 21

Neovacs SA 22

PsiOxus Therapeutics Ltd 23

ZIOPHARM Oncology Inc 24

Interferon Alpha (IFNA) - Drug Profiles 25

AGS-009 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Biosimilar to Inhibit Interferon Alpha for Lupus Erythematosus - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

NG-345 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

RTS-IFN Alpha - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Interferon Alpha (IFNA) - Dormant Projects 34

Interferon Alpha (IFNA) - Discontinued Products 35

Interferon Alpha (IFNA) - Featured News & Press Releases 36

Dec 07, 2016: Neovacs obtains FDA "Fast Track" designation for IFNa Kinoid in Lupus (SLE) 36

Nov 23, 2016: 3P Biopharmaceuticals signs production partnership with Neovacs 36

Nov 07, 2016: Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus 37

 

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.